China (Mainland)
Premiumsupplier
manufacturer Rifaximin powder CAS 80621-81-4 with wholesales price rifaximin for Anti-inflammatory CAS NO.80621-81-4
- Min.Order: 10 Gram
- Payment Terms: T/T,MoneyGram
- Product Details
Keywords
- Rifaximin
- Rifaximin powder
- CAS 80621-81-4
Quick Details
- ProName: manufacturer Rifaximin powder CAS 8062...
- CasNo: 80621-81-4
- Molecular Formula: C43H51N3O1
- Appearance: white powder
- Application: Gram positive and gram negative, aerob...
- DeliveryTime: immediately
- PackAge: aluminum foil bag
- Port: HK, Shanghai, Shenzhen
- ProductionCapacity: 100 Kilogram/Month
- Purity: 99%
- Storage: cool and dry place
- Transportation: email: wonda-chem@outlook.com
- LimitNum: 10 Gram
Superiority
1.high quality:
quality is life. quality is the most important element for all goods. we have a lab doing research in wuhan china. hplc and nmr is available if needed.
2.reasonable price:
we provide high quality products with competitive price in china. all customers are welcomed to send us inquiries and get quotation.
3.low moq:
no worry about the low moq, our moq is 1 gram or even lower.
4.good service.
fast response. we promise to reply within 24 hours including holidays and send quotation sheet and other documents within 48 hours.
5. fast shipping and secure courier.
we promise to send out products and provide tracking number within 3 working days. and we send via different couriers based on different destination countries. we usually use nl post, hk post, germany post, eub, etk, etc.
Details
| Product name |
Rifaximin |
| CAS NO. |
80621-81-4 |
| Synonyms |
Rifaximin |
| Category | Pharmaceutical Raw Materials,Active Pharmaceutical Ingredients,Bulk Drugs,Fine Chemicals. |
| Purity |
99% Rifaximin |
| Appearance |
Rifaximin powder |
| Shelf life | 2 years for Rifaximin |
| Usage |
Rifaximin is a semisynthetic antibiotic based on rifamycin. |
| Storage | Rifaximin should be stored in a well-closed container at low temperature, keep away from moisture, heat and light. |
Gram positive and gram negative, aerobic and anaerobic bacteria induced acute, chronic intestinal infection syndrome; diarrhea; intestinal microflora induced diarrhea (enterocolitis, antibiotics induced enterocolitis, traveler's diarrhea), intestinal preventive medication before and after operation, hyperammonemia, portal vein system encephalitis, liver wrong game.
Rifaximin is licensed by the U.S. Food and Drug Administration to treat traveler's diarrheacaused by E. coli. Clinical trials have shown that rifaximin is highly effective at preventing and treating traveler's diarrhea among travelers to Mexico, with few side effects and low risk of developing antibiotic resistance. It is not effective against Campylobacter jejuni, and there is no evidence of efficacy against Shigella orSalmonella species.
It may be efficacious in relieving chronic functional symptoms of bloating and flatulence that are common in irritable bowel syndrome (IBS).
There was recently a pilot-study done on the efficacy of rifaximin as a means of treatment for rosacea, according to the study, induced by the co-presence of small intestinal bacterial overgrowth.
In the United States, rifaximin has orphan drug status for the treatment of hepatic encephalopathy. Although high-quality evidence is still lacking, rifaximin appears to be as effective as or more effective than other available treatments for hepatic encephalopathy (such as lactulose), is better tolerated, and may work faster. The drawbacks to rifaximin are increased cost and lack of robust clinical trials for HE without combination lactulose therapy.
